299 related articles for article (PubMed ID: 29665189)
1. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients.
Del Bello A; Congy-Jolivet N; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Suc B; Duffas JP; Alric L; Bureau C; Danjoux M; Guilbeau-Frugier C; Blancher A; Rostaing L; Kamar N
Am J Transplant; 2014 Apr; 14(4):867-75. PubMed ID: 24580771
[TBL] [Abstract][Full Text] [Related]
3. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
[TBL] [Abstract][Full Text] [Related]
4. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.
O'Leary JG; Kaneku H; Jennings L; Susskind BM; Terasaki PI; Klintmalm GB
Liver Transpl; 2014 Jun; 20(6):655-63. PubMed ID: 24678017
[TBL] [Abstract][Full Text] [Related]
5. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
[TBL] [Abstract][Full Text] [Related]
6. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
[TBL] [Abstract][Full Text] [Related]
7. High tacrolimus intra-patient variability is associated with graft rejection, and
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
[TBL] [Abstract][Full Text] [Related]
8. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant.
Willuweit K; Heinold A; Rashidi-Alavijeh J; Heinemann FM; Horn PA; Paul A; Gerken G; Herzer K
Clin Transplant; 2017 Jun; 31(6):. PubMed ID: 28345271
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: "Liaisons dangereuses"?
Dumortier J; Dedic T; Erard-Poinsot D; Rivet C; Guillaud O; Chambon-Augoyard C; Bosch A; Lachaux A; Couchonnal E; Thaunat O; Boillot O; Dubois V
Transpl Immunol; 2019 Jun; 54():47-51. PubMed ID: 30743001
[TBL] [Abstract][Full Text] [Related]
11. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts.
OʼLeary JG; Demetris AJ; Philippe A; Freeman R; Cai J; Heidecke H; Smith C; Hart B; Jennings LW; Catar R; Everly M; Klintmalm GB; Dragun D
Transplantation; 2017 Oct; 101(10):2399-2409. PubMed ID: 28665894
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
13. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients.
Kivelä JM; Kosola S; Peräsaari J; Mäkisalo H; Jalanko H; Holmberg C; Pakarinen MP; Lauronen J
Transpl Int; 2016 Apr; 29(4):494-505. PubMed ID: 26806435
[TBL] [Abstract][Full Text] [Related]
14. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
15. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation.
Kim H; Yi NJ; Song EY; Lee K; Lee KW; Lee HW; Ahn HY; Yoon KC; Hong SK; Suh KS
Clin Transplant; 2018 May; 32(5):e13244. PubMed ID: 29577436
[TBL] [Abstract][Full Text] [Related]
16. Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients.
Levitsky J; Kaneku H; Jie C; Walsh RC; Abecassis M; Tambur AR
Am J Transplant; 2016 Aug; 16(8):2437-44. PubMed ID: 26896194
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation.
Peräsaari JP; Kyllönen LE; Salmela KT; Merenmies JM
Nephrol Dial Transplant; 2016 Apr; 31(4):672-8. PubMed ID: 26614272
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation.
Papachristou M; Fylaktou A; Daoudaki M; Cholongitas E; Karampatakis T; Anastasiou A; Chatzika G; Makrovasili F; Vagiotas L; Karakasi K; Fouzas I
Transplant Proc; 2019 Mar; 51(2):424-428. PubMed ID: 30879557
[TBL] [Abstract][Full Text] [Related]
19.
Beyzaei Z; Geramizadeh B; Bagheri Z; Karimzadeh S; Shojazadeh A
Front Immunol; 2020; 11():613128. PubMed ID: 33424868
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
